HK1252514A1 - 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 - Google Patents

包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 Download PDF

Info

Publication number
HK1252514A1
HK1252514A1 HK18111823.0A HK18111823A HK1252514A1 HK 1252514 A1 HK1252514 A1 HK 1252514A1 HK 18111823 A HK18111823 A HK 18111823A HK 1252514 A1 HK1252514 A1 HK 1252514A1
Authority
HK
Hong Kong
Prior art keywords
tumor
antibody
combination
therapeutic agent
ido inhibitor
Prior art date
Application number
HK18111823.0A
Other languages
English (en)
Chinese (zh)
Inventor
Akihiro TOKUNAGA
Toshihiko Ishii
Motoya Mie
Munetoshi Ando
Original Assignee
Kyowa Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co., Ltd. filed Critical Kyowa Kirin Co., Ltd.
Publication of HK1252514A1 publication Critical patent/HK1252514A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18111823.0A 2015-07-14 2016-07-14 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 HK1252514A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192173P 2015-07-14 2015-07-14
US62/192,173 2015-07-14

Publications (1)

Publication Number Publication Date
HK1252514A1 true HK1252514A1 (zh) 2019-05-31

Family

ID=57757291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111823.0A HK1252514A1 (zh) 2015-07-14 2016-07-14 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂

Country Status (10)

Country Link
US (2) US20180271861A1 (https=)
EP (2) EP3991749A3 (https=)
JP (2) JP2018524361A (https=)
KR (1) KR102823683B1 (https=)
CN (1) CN107847597A (https=)
AU (1) AU2016293667A1 (https=)
CA (1) CA2992238A1 (https=)
HK (1) HK1252514A1 (https=)
TW (1) TW201713332A (https=)
WO (1) WO2017010106A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070295A1 (en) 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. Anti-tim-3 antibodies and uses thereof
CN112601526B (zh) * 2018-08-29 2025-10-03 凯莫森特里克斯股份有限公司 使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677A (en) 1848-07-25 Improvement in hillside-plows
US171A (en) 1837-04-20 Machine for washing iron and other ores
US5821A (en) 1848-10-03 Cream-freezer
US4968A (en) 1847-02-13 Spinal elevator
US337A (en) 1837-07-31 Mode of constructing railroad-frogs
US603A (en) 1838-02-15 Improvement in the construction of many-chambered fire-arms
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
PT1449850E (pt) 2001-08-31 2011-02-02 Kyowa Hakko Kirin Co Ltd Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
WO2005057341A2 (en) 2003-12-02 2005-06-23 Koolspan, Inc. Automatic hardware-enabled virtual private network system
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2682382A1 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PL2315756T3 (pl) * 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2010053182A1 (ja) 2008-11-10 2010-05-14 協和発酵キリン株式会社 キヌレニン産生抑制剤
US8492119B2 (en) * 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
WO2011042065A1 (en) 2009-10-09 2011-04-14 Daniel Monsch "momoheli" lifting module and vehicles
TWI535442B (zh) * 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JP6047497B2 (ja) 2011-11-09 2016-12-21 協和発酵キリン株式会社 含窒素複素環化合物
JP6224619B2 (ja) * 2012-12-07 2017-11-01 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
CN105209449B (zh) * 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
EA029126B1 (ru) 2013-07-01 2018-02-28 Бристол-Майерс Сквибб Компани Ингибиторы ido
DK3066085T3 (da) * 2013-11-08 2020-06-02 Incyte Holdings Corp Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
EP3153178A4 (en) 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug

Also Published As

Publication number Publication date
JP2021191780A (ja) 2021-12-16
JP2018524361A (ja) 2018-08-30
EP3991749A3 (en) 2022-08-24
CN107847597A (zh) 2018-03-27
JP7366093B2 (ja) 2023-10-20
EP3991749A2 (en) 2022-05-04
EP3322444A1 (en) 2018-05-23
KR102823683B1 (ko) 2025-06-23
US20220088011A1 (en) 2022-03-24
KR20180025897A (ko) 2018-03-09
EP3322444A4 (en) 2019-06-12
CA2992238A1 (en) 2017-01-19
TW201713332A (zh) 2017-04-16
WO2017010106A1 (en) 2017-01-19
AU2016293667A1 (en) 2018-01-04
US20180271861A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12018500642A1 (en) Anti-garp antibody
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
TW201613578A (en) Pharmaceutical combinations
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
PH12016502352A1 (en) Pharmaceutical composition
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EP2786765A3 (en) Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor